Sign In

Hematologic Malignancies

Blincyto’s Role in the Management of Adult B-Cell Acute Lymphoblastic Leukemia

FDA Approval of Danziten: A Breakthrough in Chronic Myeloid Leukemia Management

Insights from the AURIGA Trial: Daratumumab-Based Maintenance Therapy in Newly Diagnosed Multiple Myeloma

Dr. Rodrigo C. Leão Edelmuth

Obecabtagene Autoleucel: A New Frontier in Treating Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia

Talvey: A Promising Treatment for Relapsed/Refractory Multiple Myeloma

Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma

Treatment Sequencing and Potential New Combination Options for Chronic Lymphocytic Leukemia

Amplify Phase III Trial: Comprehensive Overview and Clinical Significance for CLL Patients

A Better Medication For Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma: Zanubrutinib

Integrating Venetoclax into CLL Management is Expanding Treatment Horizons and Improving Survival

Distinguishing Between Acute And Chronic Myeloid Leukemia

Choosing Between a BTK Inhibitor & Car T-Cell Therapy

Insights & Perspectives

Latest Therapies For Managing Patients With Treatment-Naive CLL: Comparing Calquence, Imbruvica, and Brukinsa

Staying Connected & Sharing Knowledge: How Community Doctors Can Stay on Top of the Latest in CLL Research

For Treatment-Naïve CLL: The Risks & Benefits of Time-Limited Therapy vs. Continuous Therapy

When To Treat Chronic Lymphocytic Leukemia (CLL)?

Improving Quality of Life for Immunocompromised CLL Patients

Continuous Therapy Options For CLL: Acalabrutinib vs. Zanubrutinib

Sarclisa Gets FDA Approval for Newly Diagnosed Multiple Myeloma — When to Use a Four-Drug Regimen

Equitable Care in Multiple Myeloma Patients: Is Talvey a Good Option for Black Patients?

Bispecific Antibodies Challenge CAR T-Cell Therapy as Multiple Myeloma Treatment Contender

Where Does Belantamab Fit in Multiple Myeloma Treatment Paradigm for Relapse? Excitement Over 48% Reduction in Disease Progression

Mutliple Myeloma: Sequencing CAR T-Cell Therapy & Bispecific Antibodies

Choosing the Best Treatment Path in the Relapsed/Refractory Multiple Myeloma Setting

How Do Two CAR T-Cell Therapies Stack Up When Comparing Results Across Trials?

Bispecific Antibodies — The Thunderdome of Myeloma

A Breakthrough for ALL

Treatment

FDA Approval of Revumenib: A New Era for Relapsed/Refractory Acute Leukemia

The FDA’s recent approval of revumenib (brand name Revuforj), a menin inhibitor, marks a significant advancement in the treatment of adult and pediatric patients aged...

A New Era in Treating Newly Diagnosed Chronic Myeloid Leukemia: The Promise of Asciminib

New Developments In Tyrosine Kinase Inhibitor Therapy (TKI) for Chronic Myeloid Leukemia (CML)

Monitoring Patients During Oral Treatment for CML

The Different Phases Of Chronic Myeloid Leukemia & Their Management

Clinical Updates & Perspectices

The Evolving Management of Anemia in Myelofibrosis

The Latest in Managing Anemia for Patients With Myelodysplastic Syndrome

Rytelo Gains FDA Approval for Lower-Risk Myelodysplastic Syndrome: Reducing Need For Blood Transfusions & Improving Quality of Life

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

ASCO: Study Finds Ibrutinib Can Improve Outcomes In Some Newly Diagnosed Patients With Mantle Cell Lymphoma

Learn How to Build Trust and Reduce Racial Disparities in Multiple Myeloma

Addressing Disparities

Treatment

Black Participation in Clinical Trials Is Imperative to Reduce Racial Disparities in Multiple Myeloma

By Kayle Waterhouse African Americans must be properly represented in clinical trials to ensure equal treatment for multiple myeloma and other cancers, top oncologists told SurvivorNet...